32
SK Biopharm
326030.KS·KRXSeongnam KRFounded 1993600 employees
Mid CappharmaPublicCNSNeurology
Platform: Cenobamate Epilepsy
Market Cap
$3B
All Drugs
3
Clinical Trials
7
Failed / Terminated
0
FDA Approved
1
Stock Price & Catalysts (326030.KS)
Loading 326030.KS stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Fixaratamab | 326-9866 | Approved | 4 | TYK2 | Endometrial Ca | ||
| Sovazanubrutinib | 326-983 | Phase 2/3 | 2 | CDK2 | SMANB | ||
| Polafotisoran | 326-3805 | NDA/BLA | 1 | TNFα | HSThymoma |
SEC Filings & Financial Documents
SEC filings are not available for KRX-listed companies.
SK Biopharm trades on KRX (KR). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (6)